Compound Radar

Novavax, Inc. (NVAX) Stock Analysis

United States · Healthcare / Biotechnology

Price $10.19
Market cap $1.68B
Next earnings Nov 5, 2026
Entry status Wait $8.33–$8.85

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

62
62/100 Good Quality
  • Financial Health 85
  • Profitability 70
  • Business Quality 50
  • Balance Sheet 65
  • Cash Flow 25

Why this rating?

Health 62/100 — Good Quality

Strongest Financial Health 85/100
Softest Cash Flow 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Novavax, Inc. (NVAX) is a Biotechnology company in the Healthcare sector. Compound Radar rates Novavax, Inc. 62/100 (Good Quality) due to solid business quality and manageable leverage.

Investment profile

  • Quality Moderate
  • Growth Soft
  • Balance Sheet Adequate

Financial highlights

Valuation

  • Forward P/E -16.6
  • PEG 1.32
  • EV/Revenue 3.05

Profitability

  • Revenue Growth -76.3%
  • Gross Margin -2.6%
  • Operating Margin -89.6%
  • Net Margin -59.9%

Financial strength

  • Cash $719.34M
  • Debt $297.32M
  • Net Cash $422.02M
  • Free Cash Flow $-251.02M
  • Current Ratio 2.33

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Novavax, Inc. (NVAX).

View Methodology & FAQ →